ECM
GTBP icon

ExodusPoint Capital Management’s GT Biopharma GTBP Stock Holding History

ExodusPoint Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-740
Closed -$150K – 2337
2021
Q3 		$150K Buy
+740
New +$223K ﹤0.01% 1838

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ExodusPoint Capital Management's GTBP Position: Q4 2021 in Review

ExodusPoint Capital Management sold out of GT Biopharma (GTBP) in Q4 2021, closing a stake of 740 shares — an estimated $150K sold.

ExodusPoint Capital Management first reported a position in GTBP in Q3 2021 and held it in 1 quarter. The position peaked at $150K in Q3 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q4 2021.

  • ExodusPoint Capital Management reported no remaining GT Biopharma position as of Q4 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 740 GT Biopharma shares in Q4 2021, an estimated $150K.
  • ExodusPoint Capital Management first reported a position in GT Biopharma in Q3 2021 and held it in 1 quarter.
  • ExodusPoint Capital Management's GT Biopharma position peaked at $150K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.